Cargando…

The Dependence of Renal (68)Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with (177)Lu[Lu]-DOTATOC

Background: In addition to its SSTR-specific binding in tumors and healthy tissues, DOTATOC analogues accumulate in kidney parenchyma. Renal tracer uptake might be a surrogate of kidney function or dysfunction. This study aimed to evaluate if kidney function can be estimated from (68)Ga[Ga]-DOTATOC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gühne, Falk, Heinzig, Alexander, Seifert, Philipp, Drescher, Robert, Freesmeyer, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307408/ https://www.ncbi.nlm.nih.gov/pubmed/34359299 http://dx.doi.org/10.3390/diagnostics11071216

Ejemplares similares

[(68)Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [(177)Lu]DOTATOC PRRT: The “Theragnomics” Concept
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Effect of Peptide Dose on Radiation Dosimetry for Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATOC: A Pilot Study
por: Prasad, Vikas, et al.
Publicado: (2021)

(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans
por: Uccelli, Licia, et al.
Publicado: (2021)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC
por: Galler, Markus, et al.
Publicado: (2022)

Prospective data-driven respiratory gating of [(68)Ga]Ga-DOTATOC PET/CT
por: Sigfridsson, Jonathan, et al.
Publicado: (2021)

Relevance of Volumetric Parameters Applied to [(68)Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
por: Urso, Luca, et al.
Publicado: (2023)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

[(68)Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
por: Gehler, Barbara, et al.
Publicado: (2009)

Pindborg Tumor—An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC
por: Herden, Anna, et al.
Publicado: (2022)

Meningiomas: A Comparative Study of (68)Ga-DOTATOC, (68)Ga-DOTANOC and (68)Ga-DOTATATE for Molecular Imaging in Mice
por: Soto-Montenegro, María Luisa, et al.
Publicado: (2014)

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
por: Baum, Richard P., et al.
Publicado: (2016)

The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
por: Ruhwedel, Tristan, et al.
Publicado: (2021)

Role of (68)Ga-DOTATOC PET/CT in the Evaluation of Primary Pulmonary Carcinoids
por: Jindal, Tarun, et al.
Publicado: (2010)

Evaluation of the Possible Utilization of (68)Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer
por: Zolghadri, Samaneh, et al.
Publicado: (2018)

CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor /[(177)Lu]Lu-Pentixather
por: Jacobs, Sarah M., et al.
Publicado: (2021)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

Diagnosis of Men-I Syndrome on (68)Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE
por: kumar Gupta, Santosh, et al.
Publicado: (2012)

Usefulness of (68)Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia
por: Lee, Dong Yun, et al.
Publicado: (2021)

Thyroid metastasis from lung carcinoid detected by (68)Ga-DOTATOC PET/CT
por: Albano, Domenico, et al.
Publicado: (2021)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Automated radiosynthesis of [(68)Ga]Ga‐PSMA‐11 and [(177)Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module for clinical applications
por: Wichmann, Christian W., et al.
Publicado: (2020)

Artificial intelligence-based (68)Ga-DOTATOC PET denoising for optimizing (68)Ge/(68)Ga generator use throughout its lifetime
por: Quak, Elske, et al.
Publicado: (2023)

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review
por: Lancellotti, Francesco, et al.
Publicado: (2019)

Correction: (68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Publicado: (2022)

Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with (68)Ga-DOTATOC PET/CT
por: Horowitz, Tatiana, et al.
Publicado: (2023)

PET/CT with [(68)Ga]gallium-oxine-labeled heat-denatured red blood cells for detection of dystopic splenic tissue
por: Freesmeyer, Martin, et al.
Publicado: (2020)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Multimodal Characterization of a PSMA-Positive Thyroid Nodule Using (68)Ga-PSMA and (124)Iodine PET/US Fusion Imaging
por: Freesmeyer, Martin, et al.
Publicado: (2022)

Differences in Distribution and Detection Rate of the [(68)Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
por: Gühne, Falk, et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment
por: Peters, Steffie M. B., et al.
Publicado: (2021)

Staging of neuroendocrine tumours: comparison of [(68)Ga]DOTATOC multiphase PET/CT and whole-body MRI
por: Schraml, C., et al.
Publicado: (2013)

Primary phosphaturic mesenchymal tumour of the lumbar spine: utility of (68)Ga-DOTATOC PET/CT findings
por: Maehara, Junki, et al.
Publicado: (2016)

Comparison of diagnostic value of 68 Ga-DOTATOC PET/MRI and standalone MRI for the detection of intracranial meningiomas
por: Einhellig, Heike C., et al.
Publicado: (2021)

Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition
por: Graef, Josefine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pgbpj2ldmpejgilf80f351f8v4